Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | ADCY8 | P40145 | 2/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528380 | 1.00 | TAS2R14 (0.50) | TAS2R14ALKBH5RARBTSHRRXRA | |
| SCHEMBL23166542 | 0.92 | TAS2R14 (0.45) | TAS2R14ALKBH5RARBTSHRRXRA | |
| SCHEMBL27803229 | 0.86 | HTT (0.48) | TAS2R14ALKBH5SRD5A2ADCY8ADCY1 | |
| SCHEMBL312837 | 0.85 | TSHR (0.47) | RARBTSHRRXRARXRBRXRG | |
| SCHEMBL30182007 | 0.85 | TSHR (0.47) | RARBTSHRRXRARXRBRXRG | |
| SCHEMBL31085070 | 0.85 | KIF11 (0.51) | TAS2R14ALKBH5ADCY8ADCY1GPBAR1 | |
| SCHEMBL313001 | 0.85 | KIF11 (0.51) | TAS2R14ALKBH5ADCY8ADCY1GPBAR1 | |
| SCHEMBL29561577 | 0.83 | PARP1 (0.44) | TAS2R14ALKBH5ADCY8ADCY1GPBAR1 | |
| SCHEMBL15314434 | 0.83 | ADCY8 (0.43) | TAS2R14ALKBH5RARBADCY8ADCY1 | |
| SCHEMBL2891169 | 0.83 | ADCY8 (0.43) | TAS2R14ALKBH5ADCY8ADCY1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-2444069-B1 | Controlled release compositions | EVONIK CORP (US) | 2019-06-05 | — | — | EP | claimed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | claimed |
| EP-1651136-B1 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | EVONIK CORP (US) | 2017-03-08 | — | — | EP | claimed |
| US-8900636-B2 | Controlled release compositions | EVONIK CORPORATION (US) | 2014-12-02 | — | — | US | claimed |
| US-8871269-B2 | Method for the preparation of controlled release formulations | EVONIK CORPORATION (US) | 2014-10-28 | — | — | US | claimed |
| CN-102612362-A | Controlled release formulations of lipocalin muteins | PIERIS AG | 2012-07-25 | — | — | CN | claimed |
| EP-2462896-A1 | Method for the preparation of controlled release formulations | PR Pharmaceuticals Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2444069-A1 | Controlled release compositions | PR Pharmaceuticals Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| EP-1651136-A4 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR PHARMACEUTICALS INC (US) | 2009-07-08 | — | — | EP | claimed |
| EP-1656115-A4 | CONTROLLED RELEASE COMPOSITIONS | PR PHARMACEUTICALS (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070092574-A1 | Controlled released compositions | PR PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | claimed |
| JP-2006528179-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060228414-A1 | Method for the preparation of controlled release formulations | PR PHAMACEUTICALS, INC (US) | 2006-10-12 | — | — | US | claimed |
| EP-1656115-A2 | CONTROLLED RELEASE COMPOSITIONS | PR Pharmaceuticals (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1651136-A2 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR Pharmaceuticals (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009356-A2 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009357-A2 | CONTROLLED RELEASE COMPOSITIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| EP-4746849-A1 | PHARMACEUTICAL COMPOSITIONS OF INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4702045-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4673133-A2 | PREPARATION OF 3,4,5-TRISUBSTITUTED TRIAZOLES AND METHODS OF USING THE SAME | University of Florida Research Foundation, Incorporated (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4227313-B1 | 1-HYDROXY-4-(TRIFLUOROMETHYL)-1,3-DIHYDROBENZO[C] [1,2]OXABOROLE-6-CARBOXYLIC ACID AND ITS USE IN THE SYNTHESIS OF GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| WO-2025016992-A1 | PHARMACEUTICAL COMPOSITIONS OF INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024223511-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2024-10-31 | — | — | WO | disclosed |
| US-12115152-B2 | Pan-RAF kinase inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2024-10-15 | — | — | US | disclosed |
| WO-2024182724-A2 | PREPARATION OF 3,4,5-TRISUBSTITUTED TRIAZOLES AND METHODS OF USING THE SAME | Universtiy of Florida Research Foundation, Incorporated (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-115141197-B | 3-aromatic heterocycle substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| CN-117624207-A | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| CN-111315751-B | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023224371-A1 | NOVEL OXADIAZOLE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES COMPRISING SAME | (주)셀로스바이오텍 | 2023-11-23 | — | — | WO | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| US-11731988-B2 | Method for producing an organic electronic component, and organic electronic component | NOVALED GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227313-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227313-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2023-08-16 | — | — | EP | disclosed |
| CN-116354993-A | Reactive Oxygen Species (ROS) responsive cations and their use in siRNA delivery | 中国科学院合肥物质科学研究院 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348464-A | Benzimidazolone GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3707145-B1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-06-21 | — | — | EP | disclosed |
| CN-111606887-B | Novel kinase inhibitor | 安徽中科拓苒药物科学研究有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-3246327-B1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIV (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-113264945-B | Spiro derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-115141197-A | 3-aromatic heterocyclic substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-109111395-B | Novel BCR-ABL kinase inhibitor | 中国科学院合肥物质科学研究院 | 2022-08-30 | — | — | CN | disclosed |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-08-09 | — | — | US | disclosed |
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| US-20220143001-A1 | NOVEL PAN-RAF KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220143001-A1 | NOVEL PAN-RAF KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2022-03-17 | — | — | US | disclosed |
| EP-3946363-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2022-02-09 | — | — | EP | disclosed |
| CN-108290879-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3932913-A1 | NEW-TYPE PAN-RAF KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2021-11-30 | — | — | US | disclosed |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2021-11-30 | — | — | US | disclosed |
| CN-111138402-B | Preparation method of isocoumarin derivative | 苏州大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-113646329-A | Glucose-sensitive insulin derivatives | 诺和诺德股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113264945-A | Spiro derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-20210198285-A1 | Method for Producing an Organic Electronic Component, and Organic Electronic Component | NOVALED GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| US-11040988-B2 | Method for producing an organic electronic component, and organic electronic component | NOVALED GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| WO-2020201041-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | WO | disclosed |
| EP-3707145-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2020-09-16 | — | — | EP | disclosed |
| CN-111606887-A | Novel kinase inhibitor | 安徽中科拓苒药物科学研究有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-107207473-B | Compounds having muscarinic receptor antagonist and β 2 adrenergic receptor agonist activity | 奇斯药制品公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111315751-A | Glucose-sensitive albumin binding derivatives | 诺沃挪第克公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111138402-A | Preparation method of isocoumarin derivative | 苏州大学 | 2020-05-12 | — | — | CN | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3201959-B1 | ORGANIC ELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-2444069-B1 | Controlled release compositions | EVONIK CORP (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3484879-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2019-05-22 | — | — | EP | disclosed |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University (CN) | 2019-04-23 | — | — | US | disclosed |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University (CN) | 2019-04-23 | — | — | US | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| CN-105837575-B | 3- acetenyl Pyrazolopyrimidine derivative and its preparation method and application | 四川大学 | 2019-01-15 | — | — | CN | disclosed |
| CN-109111395-A | Novel BCR-ABL kinase inhibitor | 中国科学院合肥物质科学研究院 | 2019-01-01 | — | — | CN | disclosed |
| EP-2550958-B1 | Controlled release formulations of lipocalin muteins | PIERIS PHARMACEUTICALS GMBH (DE) | 2018-10-10 | — | — | EP | disclosed |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-3350177-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| CN-108290879-A | Heteroaryl compound and application thereof as IRAK inhibitor | 默克专利有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| CN-104844566-B | A kind of kinase inhibitor of new structure | 合肥中科普瑞昇生物医药科技有限公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| EP-3013797-B1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-01-03 | — | — | EP | disclosed |
| EP-3256464-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| EP-3246327-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Si Chuan University (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170327516-A1 | Method for Producing an Organic Electronic Component, and Organic Electronic Component | OSRAM OLED GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170317288-A1 | Method for Producing an Organic Electronic Component, and Organic Electronic Component | NOVALED GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIVERSITY (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIVERSITY (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIVERSITY (CN) | 2017-10-26 | — | — | US | disclosed |
| CN-107207473-A | Compounds having muscarinic receptor antagonist and beta 2 adrenergic receptor agonist activity | 奇斯药制品公司 | 2017-09-26 | — | — | CN | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| CN-104822658-B | Fused Tricyclic Amides as Multiple Kinase Inhibitors | 百济神州有限公司 | 2017-08-08 | — | — | CN | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20170166517-A1 | Process for Preparing N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic Acid Ethyl Ester | NOVARTIS AG (CH) | 2017-06-15 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| CN-106573929-A | 1h-1,8- naphthyridin-2ones as anti proliferative compounds | 纳科法尔马有限公司 | 2017-04-19 | — | — | CN | disclosed |
| EP-3152205-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | Natco Pharma Limited (IN) | 2017-04-12 | — | — | EP | disclosed |
| US-9604914-B2 | Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| EP-1651136-B1 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | EVONIK CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| CN-106188005-A | Containing triazole heterocycle compound and its preparation method and application | 天津国际生物医药联合研究院 | 2016-12-07 | — | — | CN | disclosed |
| CN-106139123-A | The control delivery formulations of lipocalin mutein albumen | 爱力根公司 | 2016-11-23 | — | — | CN | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| WO-2016149111-A1 | TREATING LATENT AUTOIMMUNE DIABETES OF ADULTS WITH FARNESOID X RECEPTOR AGONISTS TO ACTIVATE INTESTINAL RECEPTORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| WO-2016128456-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | WO | disclosed |
| CN-105837575-A | 3-ethynyl pyrazolo pyrimidine derivative and preparation method and application thereof | 四川大学 | 2016-08-10 | — | — | CN | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| WO-2016112846-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | 四川大学 | 2016-07-21 | — | — | WO | disclosed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | disclosed |
| EP-3013797-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016050330-A1 | METHOD FOR PRODUCING AN ORGANIC ELECTRONIC COMPONENT, AND ORGANIC ELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| CN-103415507-B | As the 3-amino-pyridine class of GPBAR1 agonist | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-02 | — | — | CN | disclosed |
| CN-103097365-B | 5- (biphenyl-4-yl) -3-phenyl-1, 2, 4-oxadiazolyl derivatives as ligands on sphingosine-1-phosphate (S1P) receptors | MERCK SERONO S.A. (CH) | 2016-02-24 | — | — | CN | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
| CN-105143193-A | Biaryl or heterocyclic biaryl substituted cyclohexene derivative compounds as CETP inhibitors | CHONG KUN DANG PHARM CORP | 2015-12-09 | — | — | CN | disclosed |
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937335-A1 | HETEROCYCLIC AMIDE DERIVATIVE, AND MEDICINE CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2015-10-08 | — | — | US | disclosed |
| CN-102803238-B | Oxadiazole Derivatives | MERCK SERONO S.A. (CH) | 2015-09-30 | — | — | CN | disclosed |
| CN-104844566-A | Kinase inhibitor with novel structure | HEFEI INST PHYSICAL SCI CAS | 2015-08-19 | — | — | CN | disclosed |
| CN-104822658-A | Fused Tricyclic Amides as Multiple Kinase Inhibitors | BEIGENE LTD | 2015-08-05 | — | — | CN | disclosed |
| CN-103121972-B | As the pyrimidine urea derivatives of kinase inhibitor | NOVARTIS AG (CH) | 2015-07-29 | — | — | CN | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2015-06-04 | — | — | US | disclosed |
| EP-2681194-B1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8987307-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2015034271-A1 | NOVEL ANTIFUNGAL PYRIDINYLHYDRAZIDE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-03-12 | — | — | WO | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-104379560-A | Benzamide derivative | CHUGAI PHARMACEUTICAL CO LTD | 2015-02-25 | — | — | CN | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8900636-B2 | Controlled release compositions | EVONIK CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2231619-B1 | INHIBITORS OF STEAROYL-COA DESATURASE | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-8871269-B2 | Method for the preparation of controlled release formulations | EVONIK CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014102377-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102378-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2681194-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| CN-103421005-A | Acetylene derivative capable of resisting activity of tumor | SHANGHAI PHARMACEUTICAL GROUP CO LTD | 2013-12-04 | — | — | CN | disclosed |
| CN-103415507-A | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-8557776-B2 | Compounds and methods for 18F labeled agents | Bayer Pharma AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| EP-2576566-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | MSD Oss B.V. (NL) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2563779-A1 | INSECTICIDAL ARYLPYRROLINE COMPOUNDS | Bayer CropScience AG (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2550958-A1 | Controlled release formulations of lipocalin muteins | Pieris AG (DE) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-102725286-A | Insecticidal arylpyrroline compounds | BAYER CROPSCIENCE AG | 2012-10-10 | — | — | CN | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120201873-A1 | CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS | PIERIS AG (DE) | 2012-08-09 | — | — | US | disclosed |
| CN-101896473-B | Inhibitors of stearoyl-coa desaturase | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| CN-102612362-A | Controlled release formulations of lipocalin muteins | PIERIS AG | 2012-07-25 | — | — | CN | disclosed |
| EP-2462896-A1 | Method for the preparation of controlled release formulations | PR Pharmaceuticals Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2461800-A2 | CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS | Pieris AG (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| EP-2444069-A1 | Controlled release compositions | PR Pharmaceuticals Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| CN-102421754-A | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO LTD | 2012-04-18 | — | — | CN | disclosed |
| US-8158560-B2 | Insecticidal arylpyrroline compounds | BAYER CROPSCIENCE AG (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158560-B2 | Insecticidal arylpyrroline compounds | BAYER CROPSCIENCE AG (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158560-B2 | Insecticidal arylpyrroline compounds | BAYER CROPSCIENCE AG (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| CN-101456841-B | Amide derivative and medicine | NIPPON SHINYAKU CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2396325-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | OriBase Pharma (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011154846-A2 | COMPOUND, SYNTHESIS, COMPOSITION AND USES THEREOF | KANDULA MAHESH (IN) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20110281893-A1 | COMPOUND, SYNTHESIS, COMPOSITION AND USES THEREOF | KRISANI BIOSCIENCES (P) LTD (IN) | 2011-11-17 | — | — | US | disclosed |
| US-20110281893-A1 | COMPOUND, SYNTHESIS, COMPOSITION AND USES THEREOF | KRISANI BIOSCIENCES (P) LTD (IN) | 2011-11-17 | — | — | US | disclosed |
| CN-101448791-B | Fxr agonists | LILLY CO ELI | 2011-11-16 | — | — | CN | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110118319-A1 | Insecticidal Arylpyrroline Compounds | BAYER CROPSCIENCE AG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118319-A1 | Insecticidal Arylpyrroline Compounds | BAYER CROPSCIENCE AG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118319-A1 | Insecticidal Arylpyrroline Compounds | BAYER CROPSCIENCE AG (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011054871-A1 | INSECTICIDAL ARYLPYRROLINE COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054871-A1 | INSECTICIDAL ARYLPYRROLINE COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2011-05-12 | — | — | WO | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011015634-A2 | CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS | PIERIS AG (DE) | 2011-02-10 | — | — | WO | disclosed |
| US-20110034524-A1 | HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2185512-B1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-29 | — | — | EP | disclosed |
| CN-101896473-A | Inhibitors of stearoyl-coa desaturase | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2231619-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
| CN-101790515-A | trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD | 2010-07-28 | — | — | CN | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-2185512-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-19 | — | — | EP | disclosed |
| CN-101696188-A | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG | 2010-04-21 | — | — | CN | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-7652013-B2 | Inhibitors of stearoyl-CoA desaturase | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| CN-100526298-C | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| EP-1651136-A4 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR PHARMACEUTICALS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1656115-A4 | CONTROLLED RELEASE COMPOSITIONS | PR PHARMACEUTICALS (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| CN-101456841-A | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2009-06-17 | — | — | CN | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
| CN-101448791-A | FXR agonists | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009016560-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| CN-101341133-A | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | ASTRAZENECA AB (SE) | 2009-01-07 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1934217-A1 | NEW COMPOUNDS II | Astra Zeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146570-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| CN-101146789-A | Compound (I) | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | CN | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| CN-101048388-A | Quinazolinone derivatives and their use as B-Raf inhibitors | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| CN-101039914-A | Trifluoromethyl substituted benzamide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-19 | — | — | CN | disclosed |
| EP-1831198-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-101035769-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20070092574-A1 | Controlled released compositions | PR PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007040439-A1 | NEW COMPOUNDS II | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| CN-1922151-A | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2007-02-28 | — | — | CN | disclosed |
| CN-1898208-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060228414-A1 | Method for the preparation of controlled release formulations | PR PHAMACEUTICALS, INC (US) | 2006-10-12 | — | — | US | disclosed |
| JP-2006265133-A | METHOD FOR PRODUCING 4-METHYL-3-TRIFLUOROMETHYLBENZOIC ACID | CENTRAL GLASS CO LTD | 2006-10-05 | — | — | JP | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-7087601-B2 | Metabotropic glutamate receptor-5 modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1656115-A2 | CONTROLLED RELEASE COMPOSITIONS | PR Pharmaceuticals (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1651136-A2 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR Pharmaceuticals (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-1453815-A4 | METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050065340-A1 | Metabotropic glutamate receptor-5 modulators | MERCK SHARP & DOHME CORP. | 2005-03-24 | — | — | US | disclosed |
| WO-2005009357-A2 | CONTROLLED RELEASE COMPOSITIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009356-A2 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1453815-A1 | METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS | Merck & Co., Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003048137-A1 | METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | GPBAR1, ADRA1B, GPR119 | TAS2R14 1391/4885ALKBH5 1975/4885RARB 582/4885 |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TAS2R14 1174/4885ALKBH5 4736/4885RARB 214/4885 |
| US-20110034524-A1 | HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR | S1PR1, S1PR2, S1PR3 | TAS2R14 1038/4885ALKBH5 4721/4885RARB 3611/4885 |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | TAS2R14 3966/4885ALKBH5 1729/4885RARB 2634/4885 |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | TAS2R14 1742/4885ALKBH5 2300/4885RARB 3569/4885 |
| US-20050065340-A1 | Metabotropic glutamate receptor-5 modulators | GRM5, GRIK5, GRM1 | TAS2R14 1008/4885ALKBH5 2528/4885RARB 440/4885 |
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | IAPP, IRS1, GPR119 | TAS2R14 3045/4885ALKBH5 4559/4885RARB 4130/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | TAS2R14 1391/4885ALKBH5 1975/4885RARB 582/4885 |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TAS2R14 1113/4885ALKBH5 4602/4885RARB 219/4885 |
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | TAS2R14 3578/4885ALKBH5 2857/4885RARB 3518/4885 |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | TAS2R14 3293/4885ALKBH5 4179/4885RARB 1480/4885 |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAS2R14 4534/4885ALKBH5 2980/4885RARB 2927/4885 |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | TAS2R14 4359/4885ALKBH5 4675/4885RARB 3283/4885 |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K3, MAP3K20 | TAS2R14 4542/4885ALKBH5 1581/4885RARB 3056/4885 |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | TAS2R14 3910/4885ALKBH5 2891/4885RARB 2114/4885 |
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | TRPA1, TRPV1, TRPV2 | TAS2R14 394/4885ALKBH5 3854/4885RARB 1523/4885 |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | TAS2R14 4224/4885ALKBH5 2942/4885RARB 2781/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAS2R14 4534/4885ALKBH5 2980/4885RARB 2927/4885 |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | TAS2R14 160/4885ALKBH5 4385/4885RARB 1016/4885 |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TAS2R14 3058/4885ALKBH5 1939/4885RARB 1432/4885 |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | TAS2R14 385/4885ALKBH5 379/4885RARB 2641/4885 |
| US-20170327516-A1 | Method for Producing an Organic Electronic Component, and Organic Electronic Component | OR10J3, AP2M1, OPRM1 | TAS2R14 2191/4885ALKBH5 901/4885RARB 2327/4885 |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | TAS2R14 4224/4885ALKBH5 2942/4885RARB 2781/4885 |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | ABL1, DDR1, ABL2 | TAS2R14 1680/4885ALKBH5 1347/4885RARB 1689/4885 |
| US-11040988-B2 | Method for producing an organic electronic component, and organic electronic component | EPCAM, OSTC, L1CAM | TAS2R14 3016/4885ALKBH5 1390/4885RARB 607/4885 |
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TAS2R14 1230/4885ALKBH5 3354/4885RARB 975/4885 |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | TAS2R14 3857/4885ALKBH5 4619/4885RARB 617/4885 |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, PYGB, GSK3A | TAS2R14 3732/4885ALKBH5 4272/4885RARB 3400/4885 |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | TAS2R14 4224/4885ALKBH5 2942/4885RARB 2781/4885 |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | TAS2R14 4811/4885ALKBH5 4637/4885RARB 4368/4885 |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | TAS2R14 3145/4885ALKBH5 2879/4885RARB 1854/4885 |
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | DPYD, TYMP, WEE1 | TAS2R14 3793/4885ALKBH5 1412/4885RARB 4574/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | TAS2R14 4811/4885ALKBH5 4637/4885RARB 4368/4885 |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | DPYD, TYMP, WEE1 | TAS2R14 3793/4885ALKBH5 1412/4885RARB 4574/4885 |
| US-11731988-B2 | Method for producing an organic electronic component, and organic electronic component | AP2M1, OR10J3, OPRM1 | TAS2R14 2318/4885ALKBH5 881/4885RARB 1379/4885 |
| US-20210198285-A1 | Method for Producing an Organic Electronic Component, and Organic Electronic Component | AP2M1, OR10J3, OPRM1 | TAS2R14 2318/4885ALKBH5 881/4885RARB 1379/4885 |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | TAS2R14 2037/4885ALKBH5 2141/4885RARB 1482/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TAS2R14 1615/4885ALKBH5 3553/4885RARB 4085/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | TAS2R14 1095/4885ALKBH5 3214/4885RARB 2203/4885 |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | TAS2R14 4521/4885ALKBH5 1131/4885RARB 2621/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | TAS2R14 4534/4885ALKBH5 2980/4885RARB 2927/4885 |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | TAS2R14 4764/4885ALKBH5 3902/4885RARB 3941/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | TAS2R14 4811/4885ALKBH5 4637/4885RARB 4368/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | TAS2R14 747/4885ALKBH5 3241/4885RARB 1575/4885 |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | TAS2R14 4224/4885ALKBH5 2942/4885RARB 2781/4885 |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BRAF, EGFR, ERBB2 | TAS2R14 3617/4885ALKBH5 3296/4885RARB 1110/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | TAS2R14 3966/4885ALKBH5 1729/4885RARB 2634/4885 |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | TAS2R14 1391/4885ALKBH5 1975/4885RARB 582/4885 |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | TAS2R14 1381/4885ALKBH5 1441/4885RARB 285/4885 |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | ABL1, DDR1, ABL2 | TAS2R14 1718/4885ALKBH5 1367/4885RARB 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.